SLXM-2, a derivative of cyclophosphamide: mechanism of growth inhibition on hepatocarcinoma 22 cells. [electronic resource]
Producer: 20080407Description: 167-74 p. digitalISSN:- 0959-4973
- Animals
- Antineoplastic Agents, Alkylating -- administration & dosage
- Blotting, Western
- CDC2-CDC28 Kinases -- genetics
- Carcinoma, Hepatocellular -- drug therapy
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Cyclin B -- genetics
- Cyclin B1
- Cyclophosphamide -- administration & dosage
- Dose-Response Relationship, Drug
- Flow Cytometry
- G2 Phase -- drug effects
- Gene Expression -- drug effects
- Injections, Intraperitoneal
- Leukocyte Count
- Liver Neoplasms, Experimental -- drug therapy
- Male
- Mice
- Mice, Inbred ICR
- Molecular Structure
- Piperazines -- administration & dosage
- RNA, Messenger -- genetics
- Reverse Transcriptase Polymerase Chain Reaction
- S Phase -- drug effects
- Weight Loss -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.